HT
ANIP icon

Headlands Technologies’s ANI Pharmaceuticals ANIP Stock Holding History

Headlands Technologies’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,830
Closed -$756K – 718
2026
Q1 		$756K Buy
9,830
+446
+5% +$34.8K 0.09% 274
2025
Q4 		$741K Buy
9,384
+2,388
+34% +$207K 0.06% 320
2025
Q3 		$641K Buy
6,996
+3,258
+87% +$266K 0.05% 310
2025
Q2 		$244K Sell
3,738
-1,631
-30% -$106K 0.03% 436
2025
Q1 		$359K Buy
5,369
+4,171
+348% +$249K 0.04% 344
2024
Q4 		$66.2K Sell
1,198
-7,091
-86% -$407K 0.01% 758
2024
Q3 		$495K Buy
+8,289
New +$506K 0.06% 345
2024
Q2 		– Sell
-194
Closed -$13.4K – 1133
2024
Q1 		$13.4K Buy
+194
New +$11.7K ﹤0.01% 989

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Headlands Technologies's ANIP Position: Q2 2026 in Review

Headlands Technologies sold out of ANI Pharmaceuticals (ANIP) in Q2 2026, closing a stake of 9,830 shares — an estimated $756K sold.

Headlands Technologies first reported a position in ANIP in Q1 2024 and held it in 8 quarters. The position peaked at $756K in Q1 2026. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Headlands Technologies reported no remaining ANI Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 9,830 ANI Pharmaceuticals shares in Q2 2026, an estimated $756K.
  • Headlands Technologies first reported a position in ANI Pharmaceuticals in Q1 2024 and held it in 8 quarters.
  • Headlands Technologies's ANI Pharmaceuticals position peaked at $756K in Q1 2026.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.